GSK (NYSE:GSK) respiratory, immunology and inflammation R&D head Kaivan Khavandi said the company is positioning several late-stage programs around clear unmet need and what he described as better “target trait pairing,” highlighting upcoming chronic cough data, planned hepatitis B regulatory steps, and recent business development that focuses on validated biology with room for differentiation. Chronic […]